Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
06 September 2023 - 6:00AM
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad
Oncology”), today announces the below information following the
issuance, on 04 September 2023, of 3,930,770 new shares of Celyad
Oncology SA (the “Company”) to Tolefi and an affiliate of Fortress
Investment Group as well as other historical shareholders. As a
result, the Company’s share capital has been increased to
80,628,224.49 EUR and is represented by 26,524,726 shares.
This information is published in accordance with
Article 15 of the Belgian Law of 2 May 2007 on the disclosure of
major participations in issuers whose shares are admitted to
trading on a regulated market and regarding miscellaneous
provisions.Figures – Modified on 04 September 2023
following the capital Increase:
Total amount of share capital (EUR) |
80,628,224.49 |
Total Number of shares with single voting rights |
24,156,351 |
Total Number of shares with double voting rights |
2,368,375 |
Total Number of Shares |
26,524,726 |
Total of voting rights |
28,893,101 |
Total number of attributed warrants |
2,852,913 |
Total number of shares with voting rights that could be created
following the exercise of the attributed warrants |
2,852,913 |
Total number of diluted shares (Outstanding shares + Warrants) |
29,377,639 |
Total number of diluted shares with voting rights |
31,746,014 |
Contact person for regulated information
(financial, transparency)
By law, any transparency declaration must be
sent to our Company by email to the attention of Georges Rawadi,
Chief Executive Officer (CEO):
investors@celyad.com.
Further questions about the content of this
release can be sent to investors@celyad.com.
About Celyad Oncology
Celyad Oncology is a cutting-edge biotechnology
company dedicated to pioneering the discovery and advancement of
revolutionary technologies for chimeric antigen receptor (CAR)
T-cells. Its primary objective is to unlock the potential of its
proprietary technology platforms and intellectual property,
enabling to be at the forefront of developing next-generation CAR
T-cell therapies. By fully leveraging its innovative technology
platforms, Celyad Oncology aims to maximize the transformative
impact of its candidate CAR T-cell therapies and redefine the
future of CAR T-cell treatments. Celyad Oncology is based in
Mont-Saint-Guibert, Belgium. For more information, please visit
www.celyad.com.
Forward-looking statements
This release may contain forward-looking
statements, within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995, as
amended, including, without limitation, statements regarding
beliefs about and expectations for the Company’s updated strategic
business model, including associated potential benefits,
transactions and partnerships, statements regarding the potential
value of the Company’s IP, and statements regarding the
continuation of the Company’s existence. The words “will,”
“potential,” “continue,” “target,” “project,” “should” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Any forward-looking statements in this release
are based on management’s current expectations and beliefs and are
subject to a number of known and unknown risks, uncertainties and
important factors which might cause actual events, results,
financial condition, performance or achievements of Celyad Oncology
to differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include,
without limitation, risks related to the material uncertainty about
the Company’s ability to continue as a going concern; the Company’s
ability to realize the expected benefits of its updated strategic
business model; the Company’s ability to develop its IP assets and
enter into partnerships with outside parties; the Company’s ability
to enforce its patents and other IP rights; the possibility that
the Company may infringe on the patents or IP rights of others and
be required to defend against patent or other IP rights suits; the
possibility that the Company may not successfully defend itself
against claims of patent infringement or other IP rights suits,
which could result in substantial claims for damages against the
Company; the possibility that the Company may become involved in
lawsuits to protect or enforce its patents, which could be
expensive, time-consuming, and unsuccessful; the Company’s ability
to protect its IP rights throughout the world; the potential for
patents held by the Company to be found invalid or unenforceable;
and other risks identified in Celyad Oncology’s U.S. Securities and
Exchange Commission (SEC) filings and reports, including in the
latest Annual Report on Form 20-F filed with the SEC and subsequent
filings and reports by Celyad Oncology. These forward-looking
statements speak only as of the date of publication of this
document and Celyad Oncology’s actual results may differ materially
from those expressed or implied by these forward-looking
statements. Celyad Oncology expressly disclaims any obligation to
update any such forward-looking statements in this document to
reflect any change in its expectations with regard thereto or any
change in events, conditions or circumstances on which any such
statement is based, unless required by law or regulation.
Investor Contact: |
Media Contact: |
David GeorgesVP Finance and Administrationinvestors@celyad.com |
Caroline LonezR&D Communications and Business
Developmentcommunications@celyad.com |
Source: Celyad Oncology SA
Celyad Oncology (EU:CYAD)
Historical Stock Chart
From Oct 2024 to Nov 2024
Celyad Oncology (EU:CYAD)
Historical Stock Chart
From Nov 2023 to Nov 2024